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MicroRNA (miRNA) biogenesis is a highly regulated process in eukaryotic cells. Several mature miRNAs exhibit
a tissue-specific pattern of expression without an apparent tissue-specific pattern for their corresponding primary
transcripts. This discrepancy is suggestive of post-transcriptional regulation of miRNA abundance. Here, we
demonstrate that the brain-enriched expression of miR-7, which is processed from the ubiquitous hnRNP K
pre-mRNA transcript, is achieved by inhibition of its biogenesis in nonbrain cells in both human and mouse
systems. Using stable isotope labeling by amino acids in cell culture (SILAC) mass spectrometry combined with
RNase-assisted RNA pull-down, we identified Musashi homolog 2 (MSI2) and Hu antigen R (HuR) proteins as
inhibitors of miR-7 processing in nonneural cells. This is achieved through HuR-mediated binding of MSI2 to the
conserved terminal loop of pri-miR-7. Footprinting and electrophoretic gel mobility shift analysis (EMSA) provide
further evidence for a direct interaction between pri-miR-7-1 and the HuR/MSI2 complex, resulting in
stabilization of the pri-miR-7-1 structure. We also confirmed the physiological relevance of this inhibitory
mechanism in a neuronal differentiation system using human SH-SY5Y cells. Finally, we show elevated levels
of miR-7 in selected tissues from MSI2 knockout (KO) mice without apparent changes in the abundance of the
pri-miR-7 transcript. Altogether, our data provide the first insight into the regulation of brain-enriched miRNA
processing by defined tissue-specific factors.
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MicroRNAs (miRNAs) constitute a large family of short
(21- to 23-nucleotide [nt]), noncoding RNAs that regulate
gene expression and control a variety of biological pro-
cesses, including cell cycle, developmental timing, dif-
ferentiation, metabolism, neuronal patterning, and aging
(Ketting et al. 2001; Lee and Ambros 2001; Shi et al. 2010;
Pauli et al. 2011). Given their diverse functions in meta-
zoans, it is not surprising that their spatial and temporal
expression is tightly regulated (Bushati and Cohen 2007).
Importantly, several miRNAs are expressed in a tissue-
specific manner, thereby contributing to cell identity and
function (Landgraf et al. 2007).
Mature miRNAs are derived from primary transcripts
(pri-miRNAs) by sequential nuclear and cytoplasmic pro-
cessing events (Zamore and Tomari 2005). In the nucleus,
the Microprocessor complex—which contains the RNase
III Drosha (Lee et al. 2003) and its RNA-binding partner,
DGCR8 (Denli et al. 2004; Gregory et al. 2004; Han et al.
2004; Landthaler et al. 2004)—generates stem–loop pre-
cursors (pre-miRNAs) that are exported to the cytoplasm
by Exportin 5 (for review, see Kim 2004). In the cytoplasm,
the RNase III enzyme Dicer cleaves off the pre-miRNA
terminal loop (TL), leaving a miRNA duplex (Hutvagner
et al. 2001; Ketting et al. 2001). Subsequently, one strand of
this duplex is incorporated into the RNA-induced silenc-
ing complex (RISC), which targets specific mRNAs and
controls their expression by affecting either transcript
stability or translation (Hammond et al. 2000; Eulalio
et al. 2009; Fabian et al. 2010). Recently, it has become
clear that the miRNA biogenesis pathway is subjected to
regulation by a variety of protein factors. We showed
previously that hnRNP A1, a protein implicated in many
aspects of RNA processing, binds to the conserved TL
(CTL) of pri-miR-18a (Guil and Caceres 2007; Michlewski
et al. 2008) and pri-let-7a-1 (Michlewski and Caceres 2010a),
stimulating and inhibiting their processing, respectively.
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Furthermore, we identified several other pri-miRNAswith
highly conserved TLs and hypothesized that this may
reflect their requirement for auxiliary factors to regulate
their processing (Michlewski et al. 2008).
miRNA-7 resides within intron 15 of a very abundant
and ubiquitously expressed pre-mRNA that encodes the
hnRNP K protein (Yanai et al. 2005). Interestingly, its
precursor, pri-miR-7-1, harbors a highly conserved TL.
Surprisingly, in humans, miR-7 itself is enriched in brain
and pancreatic tissues despite the ubiquitous expression
of its host hnRNP K pre-mRNA (Landgraf et al. 2007; Hsu
et al. 2008). This discrepancy suggests that miR-7 expres-
sion is regulated at the post-transcriptional level. Here,
using miRNA in vitro processing assays, we show that
pri-miR-7-1 processing is inhibited in nonneural cells by
the binding of trans-acting factors to itsCTL. Stable isotope
labeling by amino acids in cell culture (SILAC) (Ong et al.
2002) has been previously demonstrated to reveal proteins
that bind specifically to phosphorylation sites (Schulze
and Mann 2004), epigenetic marks (Vermeulen et al. 2010),
and functional DNA elements (Mittler et al. 2009). Using
SILAC mass spectrometry combined with RNase-assisted
RNA pull-down, we demonstrate that the biogenesis of
brain-enrichedmiR-7 is inhibited by theMusashi homolog 2
(MSI2) and Hu antigen R (HuR) proteins, which act through
converging pathways in nonneural cells. We reveal that
MSI2 andHuR are interacting partners and provide evidence
that the role of HuR is to assist MSI2 binding, which is the
actual factor that inhibits miR-7 biogenesis. We also show
that upon HuR and MSI2 binding to pri-miR-7-1, its stem
structure becomes more rigid, suggesting a potential mech-
anism of inhibition of Microprocessor cleavage. We confirm
the physiological relevance of MSI2/HuR-mediated inhibi-
tion of miR-7 biogenesis in a neuronal differentiationmodel
of human neuroblastoma SH-SY5Y cells. Finally, we show
elevated levels ofmiR-7 but not pri-miR-7 in selected tissues
of MSI2 knockout (KO) mice. Altogether, these results
provide the first example of tissue-specific control of brain-
enriched miRNA maturation by defined factors.
Results
The biogenesis of brain-enriched miR-7 is regulated
post-transcriptionally
miR-7 resides on intron 15 of the hnRNP K pre-mRNA (Fig.
1A). According to the gene expression database GeneNote,
hnRNP K pre-mRNA is ubiquitously expressed in all
Figure 1. The biogenesis of miR-7 is regulated post-transcriptionally. (A) Schematic of the segment of the hnRNP K pre-mRNA that
harbors the pri-miR-7-1 stem–loop region in intron 15. The CTL of pri-miR-7-1 is indicated in gray. Arrows represent relative positions
of qRT–PCR primers used to measure pri-miR-7-1 levels. (B) Northern blot analysis of total RNA from astrocytoma 1321N1, 293T, and
HeLa cells shows high, medium, and low levels of miR-7, respectively. In contrast, miR-16 shows similar abundance in the three cell
lines. As a loading control, ethidium bromide staining of 5S rRNA is shown. (C) Real-time qRT–PCR on total RNA from 293T (gray
bar), HeLa (white bar), and astrocytoma 1321N1 (black bar) cells shows high, medium, and low levels of pri-mR-7-1, respectively. The
values were normalized to GAPDHmRNA levels. The fold change was plotted relative to values derived from astrocytoma cells, which
were set to 1. Mean values and standard deviations (SD) of three independent qRT–PCRs are shown.
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human tissues (Yanai et al. 2005). Despite this observation,
miR-7 appears to be present predominantly in neural and
pancreatic tissues (Landgraf et al. 2007; Hsu et al. 2008).
There are two other miR-7 loci in the human genome,
pri-miR-7-2 and pri-miR-7-3; however, their expression
relative to pri-miR-7-1 is ;100-fold lower (Yanai et al.
2005). Here, we sought to unravel the mechanism of tissue-
specific regulation of miR-7 biogenesis. We recapitulated
the tissue-specific expression ofmiR-7 in a subset of human
cell lines. In the astrocytoma cell line 1321N1, which
represents human neural tissue, miR-7 was highly abun-
dant (Fig. 1B). The expression of miR-7 in the nonneural
HeLa cell line was much lower, whereas an intermediate
level of expression was observed in human embryonic
kidney (293T) cells (Fig. 1B). In stark contrast to the levels
of mature miR-7, the relative levels of pri-miR-7-1 were
lowest in the astrocytoma cell line (Fig. 1B,C). The discrep-
ancy between the relative expression of the miR-7 primary
transcript and its corresponding mature miRNA points to
the role of post-transcriptional regulation in controlling its
abundance in a tissue-specific manner. We observed similar
levels of pre-miR-7, which could indicate that differential
Dicer processing could be the regulatory mechanism (Fig.
1B). Alternatively, miR-7 abundance could be controlled in
the nucleus by differential activity of Microprocessor, with
similar levels of pre-miR-7-1 simply reflecting that this step
is not rate-limiting.
miR-7 is inhibited by cell type-specific factors
associated with the pri-miR-7-1 TL
Tissue-specific post-transcriptional regulation of miRNA
abundance can be achieved by two nonexclusive mecha-
nisms. First, there may be a positive factor present in
a tissue or a given cell type, in which the tissue-enriched
miRNA is abundant. Second, there may be a negative
factor present in all of the tissues or cell types that harbor
low levels of this miRNA. First, we investigated a role for
Microprocessor in miR-7-1-regulated processing. We per-
formed pri-miRNA in vitro processing assays in extracts
from HeLa and astrocytoma cells. We observed that the
Microprocessor-mediated processing that results in the
production of pre-miR-7-1 was not efficient in HeLa cell
extracts (Fig. 2A), whereas the accumulation of pre-miR-
7-1 products from pri-miR-7-1 processing in astrocytoma
cell extracts was substantial (Fig. 2A). Importantly, Drosha
and DGCR8 levels were even higher in HeLa than in
astrocytoma cell extracts (Supplemental Fig. S1A). Addi-
tionally, pri-miRNA processing in HeLa cell extracts
depleted of Drosha or DGCR8 validated the identity of
the pre-miRNA products (Supplemental Fig. S2). pri-miR-
7-1 processing with equal amounts of premixed HeLa and
astrocytoma cell extracts resulted in a much lower
accumulation of pre-miR-7-1 compared with the reaction
in astrocytoma cell extracts alone (Fig. 2A). Importantly,
the same concentration of astrocytoma cell extracts
without the addition of HeLa extracts was able to support
efficient pri-miR-7-1 processing (Fig. 2A). Processing of
a control pri-let-7a-1 was more efficient in HeLa than in
astrocytoma cell extracts (Supplemental Fig. S1B). While
we cannot rule out a contribution of regulated Dicer
processing, the results presented here clearly establish that
HeLa cell extracts contain an inhibitor of Microprocessor-
mediated miR-7 processing.
The post-transcriptional regulation of miRNA biogen-
esis can be exerted by trans-acting factors that bind to the
CTL of pri-miRNAs (Michlewski et al. 2008; Krol et al.
2010). Interestingly, pri-miR-7-1 has a TL that is well
conserved throughout vertebrate species (Michlewski
et al. 2008). Therefore, we opted to investigate whether
the CTL of pri-miR-7-1 contributes to its biogenesis.
Importantly, we found that addition of an unlabeled
wild-type pri-miR-7-1 TL RNA sequence caused dere-
pression of pri-miR-7-1 processing in HeLa cell extracts
(Fig. 2B). The same competitor had only mild effects on
the in vitro processing of pri-let-7a-1 (Supplemental Fig.
S3). Importantly, a control competitor in the form of
a mutated pri-miR-7-1 harboring the TL sequence of miR-
30a (pri-let-7a-1/30a) did not cause derepression of pri-
miR-7-1 processing in HeLa cells (Fig. 2B). Accordingly,
the in vitro processing of pri-miR-7-1 harboring the CTL
from pri-miR-30a was more efficient in HeLa extracts
than wild-type pri-miR-7-1 or a pri-miR-7-1/16 TL mu-
tant (Fig. 2C,D), which could be due to its sequence
composition. In summary, these results demonstrate that
Microprocessor-mediated miR-7 processing is inhibited
by factors associated with the pri-miR-7-1 TL present in
HeLa cells. These experiments strongly suggest that the
tissue-specific control of miR-7-1 biogenesis is operating
at the level of the nuclear step of miR-7-1 biogenesis.
SILAC combined with RNase-assisted RNA pull-down
on the pri-miR-7-1 CTL identifies putative miR-7
biogenesis factors
To establish the identity of the miR-7 biogenesis factors
that may repress pre-miR-7 production in a cell type-
specific manner, we used a novel method combining
RNase-assisted RNA pull-down of a truncated wild-type
pri-miR-7-1 CTL (Michlewski and Caceres 2010b) fol-
lowed by SILACmass spectrometry. Briefly, the RNA bait
was covalently attached to agarose beads, and bound
proteins from HeLa and astrocytoma 1321N1 extracts
were eluted by RNase to enhance the specificity of the
isolation. Next, we used SILAC for quantitative compar-
ison by mass spectrometry of proteins bound to different
RNA baits or to the beads (Fig. 3A). We compared the
binding of proteins from HeLa cell extracts labeled with
heavy Arg/Lys isotopes to the pri-miR-7-1 TL with the
binding of proteins from HeLa cell extracts labeled with
light Arg/Lys isotopes to the beads. After sorting, we
identified 14 proteins with a greater than fivefold enrich-
ment of binding to the pri-miR-7-1 CTL (Fig. 3B). Signif-
icantly, all of the identified proteins were RNA-binding
proteins, some of which were already implicated in the
regulation of miRNA biogenesis (Krol et al. 2010). Next,
we used our method on the pri-miR-7-1 CTL using equal
amounts of HeLa and astrocytoma cell extracts labeled
with heavy and light Arg/Lys isotopes, respectively. The
majority of the proteins associated with the pri-miR-7-1
Choudhury et al.
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TL demonstrated similar binding efficiencies in HeLa
and astrocytoma cell extracts (Supplemental Table S1).
Notably, the MSI2 protein exhibited a twofold increase
in binding to the pri-miR-7-1 CTL in HeLa cell extracts
compared with astrocytoma cell extracts (Fig. 3B). To
demonstrate the specificity and sensitivity of our method,
we performed validation using Western blot analysis of
select identified proteins and other abundant RNA-binding
Figure 2. Processing of pri-miR-7-1 is inhibited by nonneural CTL-binding factors. (A) In vitro processing of pri-miR-7-1 in HeLa and
astrocytoma 1321N1 cell extracts. Radiolabeled primary miR-7-1 transcripts (50 3 103 cpm [counts per minute], ;20 pmol, 665 nM) were
incubated in the presence of 50% (w/v) total HeLa extract (lane 2), 50% (w/v) astrocytoma 1321N1 extract (lane 3), 25% (w/v) HeLa extract
plus 25% (w/v) astrocytoma 1321N1 extract (lane 4), or 25% (w/v) astrocytoma 1321N1 extract (lane 5). Lane 1 shows the negative control
with no extract added. Products were analyzed on an 8% polyacrylamide gel. (M) RNA size marker. (B) In vitro processing of pri-miR-7-1 is
derepressed in the presence of unlabeled truncated wild-type pri-miR-7-1. pri-miR-7-1 was incubated with HeLa extracts (lane 2) with 1 nmol
of miR-7-1 CTL (lane 3) or 1 nmol of pri-miR-7-1/30a CTL (lane 4). Lane 1 shows the negative control with no extract added. Analysis was
performed as described in A. Schematic of the RNA secondary structure of the wild-type miR-7-1 CTL and mutant miR-7-1/30a TL is shown
on the right. (C) Predicted secondary structures of wild-type pri-miR-7-1 and CTL mutants. The wild-type terminal loop sequence was
replaced with the pri-miR-16 or pri-miR-30a TLs, resulting in pri-miR-7-1/16 and pri-miR-7-1/30a hybrids, respectively. (D) The processing of
pri-miR-7-1 is inhibited by sequences present in its terminal loop. Radiolabeled pri-miR-7-1 (lane 2), pri-miR-7-1/16 (lane 4), and pri-miR-7-1/
30a (lane 6) transcripts (50 3 103 cpm, 20 pmol, 665 nM) were incubated in the presence of 50% (w/v) total HeLa extract. Lanes 1, 3, and 5
show negative controls with no extract added. Products were analyzed on an 8% polyacrylamide gel. (M) RNA size marker.
Brain-enriched miR-7 biogenesis control
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Figure 3. SILAC combined with RNase-assisted RNA pull-down reveals putative miR-7 biogenesis factors. (A) Schematic of the
method. The left panel shows the strategy used to distinguish background noise that arises from proteins binding to the agarose beads
compared with proteins that specifically bind to the miR-7-1 CTL RNA. HeLa cells were grown in ‘‘light’’ medium containing 12C6-
arginine and 12C6-lysine or in ‘‘heavy’’ medium containing
13C6-arginine and
13C6-lysine. Next, RNase-assisted RNA pull-down was
performed on either agarose beads incubated with extracts from ‘‘light’’ HeLa cells or beads with a covalently linked miR-7-1 CTL
incubated with extracts from ‘‘heavy’’ HeLa cells. After RNase treatment, the resulting supernatants were mixed and subjected to
quantitative mass spectrometry. The right panel represents a way of identifying protein factors in the extracts from different cells or
experimental conditions that differentially bind to the bait RNA. The workflow is similar to the one described above, with different
extracts, premixed and incubated with the same complexes of agarose beads with a covalently linked miR-7-1 CTL. Finally,
quantitative mass spectrometry identified RNA-binding proteins that, in the case of miR-7-1 CTL, are putative miR-7 biogenesis
factors. (B) The top graph represents the fold enrichment of proteins that bind to the miR-7-1 CTL compared with the beads alone in
experiments with ‘‘light’’ and ‘‘heavy’’ HeLa cell extracts. The fold enrichment cutoff was set to 5. The bottom graph represents the fold
enrichment of proteins that bind to the miR-7-1 CTL in experiments with ‘‘heavy’’ HeLa cell extracts compared with ‘‘light’’
astrocytoma cell extracts. (C) Western blot analysis of miR-7-1 CTL RNA pull-down with HeLa and astrocytoma cell extracts on select
proteins identified in B (HuR, MSI2, and hnRNPA1) and control proteins (SRSF1, TIA-1, PA2G4, and MSI1). Lanes 1 and 2 represent 100
mg of loading control of HeLa and astrocytoma cell extracts, respectively. Lanes 3 and 4 show reactions with beads alone. Lanes 5 and 6
represent miR-7-1 CTL RNA pull-down with HeLa and astrocytoma cells extracts, respectively.
proteins that were not identified in the assay. The HuR
(ELAVL1) and hnRNPA1 proteins were pulled down with
similar efficiency by the pri-miR-7-1 CTL in both HeLa
and astrocytoma cell extracts (Fig. 3C). Importantly, MSI2
was specifically enriched in HeLa cells compared with
astrocytoma cells. Moreover, MSI2 was also substantially
enriched in the pri-miR-7-1 CTL RNA pull-down with
HeLa cell extracts (Fig. 3B). Importantly, other abundant
RNA-binding proteins, such as serine/arginine-rich splic-
ing factor 1 (SRSF1), T-cell-restricted intracellular antigen-1
(TIA-1), proliferation-associated 2G4 (PA2G4), or MSI1,
were not pulled down by the pri-miR-7-1 CTL, which ver-
ifies the high specificity and selectivity of this method.
To further investigate the proteins that are responsible
for the post-transcriptional regulation of miR-7 biogene-
sis, we performed RNA pull-down with the pri-miR-7-1
CTL and the pri-miR-7-1/30a TL mutant (Supplemental
Fig. S4A), which exhibited different activity in the in vitro
processing assays (Fig. 2). Western blot analysis methods
showed that the binding of MSI2 to the pri-miR-7-1 CTL
was highly specific (Supplemental Fig. S4B). We observed
a substantial enrichment ofMSI2 binding to the wild-type
pri-miR-7-1 CTL compared with the pri-miR-7-1/30a TL
mutant. Interestingly, several other proteins, including
TIA1 cytotoxic granule-associated RNA-binding protein-
like 1 (TIAL1), deleted in azoospermia-associated protein
1 (DAZAP1), and HuR, were also enriched in the pri-miR-
7-1 TL pull-down, albeit to a lesser extent (data not
shown). Importantly, the binding efficiencies of hnRNP
A1 to the pri-miR-7-1 CTL and to the pri-miR-7-1/30a TL
were similar (Supplemental Fig. S4B). Furthermore, the
SRSF1 protein was pulled down by the pri-miR-7-1/30a
TL much more efficiently than by the pri-miR-7-1 CTL.
Altogether, we identified a comprehensive set of proteins
that specifically bind to the pri-miR-7-1 CTL, which we
consider putative inhibitors of miR-7 biogenesis.
HuR and MSI2 inhibit miR-7 biogenesis in vivo
through converging pathways
To determine whether these pri-miR-7-1 CTL-binding
factors function as inhibitors of miR-7 processing, we
analyzed the relative levels of mature miR-7 and pri-miR-
7-1 by quantitative RT–PCR (qRT–PCR) upon selective
depletion of HuR and/or MSI2. We monitored the effi-
ciency of siRNA-mediated depletion in HeLa cells by
Western blot analysis (Fig. 4A). The highly abundant
PA2G4 and SRSF1, which did not exhibit binding prefer-
ences for the pri-miR-7-1 CTL, served as controls. Nota-
bly, individual knockdowns of HuR and MSI2 resulted in
an approximately twofold increase in the relative abun-
dance of endogenousmiR-7 in HeLa cells, in whichmiR-7
is normally of low abundance (Fig. 4B). In contrast,
PA2G4, SRSF1, and TIAL1 knockdowns did not change
the levels of miR-7 (Fig. 4B; data not shown). Crucially,
the double knockdown of HuR and MSI2 also resulted in
an approximately twofold increase in miR-7 abundance
(Fig. 4B). The lack of cumulative effect of the double
knockdown compared with the individual knockdowns
suggests that HuR andMSI2 may regulate miR-7 levels in
vivo through converging pathways. Importantly, the
levels of let-7a miRNA remained unchanged throughout
(Fig. 4B). More importantly, the levels of both miR-7 and
let-7a primary transcripts were largely unchanged upon
knockdown of HuR, MSI2, or control proteins (Fig. 4C).
This result strongly suggests that the HuR and MSI2
proteins regulate miR-7 abundance in vivo at the post-
transcriptional level. Global small RNA sequencing
(RNA-seq) profiling of miRNAs upon MSI2 and HuR
knockdown revealed significant increases of the miR-7
levels: 172% (P-value = 1.953 1031) and 224% (P-value =
1.82 3 1066) for MSI2 and HuR, respectively (Fig. 4D).
Clustal Omega alignment of selected pri-miRNA se-
quences (pri-miR-505, pri-miR-92a-1, pri-miR-224, and
pri-miR-7-1), which code for miRNAs up-regulated by
both HuR and MSI2 knockdown, revealed a common
U-richmotif in their TLs (Supplemental Fig. S5). Although
further analysis would be required, we hypothesize that
this motif could be important for MSI2/HuR-mediated
regulation of miRNA biogenesis. Crucially, comparison of
data sets from HuR and MSI2 RNAi showed very little
difference, pointing to a cooperative mode of miRNA
biogenesis regulation by these two proteins.
HuR recruits MSI2 to the pri-miR-7-1 CTL in vitro
and in vivo
To gain further insight into the mechanism of miR-7
inhibition, we investigated whether MSI2 and HuR in-
teract with each other. We coexpressed T7 epitope-tagged
MSI2 (pCG T7-MSI2) with untagged HuR (pCDNA3-
HuR) in HeLa cells and studied their association by
immunoprecipitation–Western blot, which revealed an
efficient coimmunoprecipitation (Fig. 5A). RNase treat-
ment, validated by RT–PCR of immunoprecipitated pri-
miR-7-1, slightly decreased the efficiency of coimmuno-
precipitation of HuR, which indicates that the interaction
between MSI2 and HuR is most likely mediated through
both RNA-dependent and RNA-independent mecha-
nisms. Importantly, the reciprocal coimmunoprecipita-
tion of MSI2 by HuR confirmed this interaction (Fig. 5B).
Notably, consistent with our previous experiments, we
did not detect an interaction between MSI2 or HuR and
SRSF1 (Fig. 5A,B). We further determined whether MSI2
could still bind the pri-miR-7-1 CTL in the absence of
HuR. RNA pull-down of the pri-miR-7-1 CTL in HeLa
extracts depleted of HuR revealed that MSI2 binding
to the pri-miR-7-1 CTL was greatly reduced (Fig. 5C).
Finally, RNA immunoprecipitation assays confirmed the
MSI2 dependence on HuR to bind to the pri-miR-7-1
transcript in vivo (Fig. 5D). Intriguingly, RNAi of MSI2
and HuR resulted in a decreased association of pri-miR-7-1
with DGCR8, most likely indicating a decreased pool of
pri-miR-7 transcripts available to bind DGCR8 resulting
from an increased rate of Microprocessor activity in the
absence of either protein (Fig. 5D). Crucially, neither HuR
nor MSI2 could pull down pri-let-7a-1 in the RNA immu-
noprecipitation assay (Fig. 5E). Importantly, the level of
DGCR8 RNA immunoprecipitation with pri-let-7a-1
remained unchanged in experiments carried out on both
Brain-enriched miR-7 biogenesis control
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Figure 4. MSI2 and HuR regulate miR-7 biogenesis in vivo through converging pathways. (A) Western blot analysis of protein extracts
from HeLa cells depleted of HuR (lane 6), MSI2 (lane 7), PA2G4 (lane 8), SRSF1 (lane 9), or both HuR and MSI2 (lane 10) using RNAi.
Lanes 1–4 show serial dilutions of total protein extracts, providing estimation of the Western blot assay linearity and the limit of
detection. Lane 5 shows a mock-transfected control. Lanes 6–10 show Western blot results. (B) Real-time qRT–PCR of miRNAs from
HeLa cells depleted of HuR, MSI2, PA2G4, SRSF1, and HuR/MSI2 reveals a substantial increase in the levels of miR-7 (black bars) upon
HuR depletion, MSI2 depletion, or combined HuR/MSI2 depletion. These values were normalized to miR-16 levels. The fold change in
the corresponding miRNA abundance mediated by RNAi was plotted relative to values from a mock-transfected control, which were
set to 100. Mean values and SDs of three independent experiments are shown. No significant changes in the levels of let-7a were
observed in any case. (C) Real-time qRT–PCR on pri-miRNAs from cells depleted as in B shows a lack of substantial change in the
relative levels of the corresponding pri-miR-7-1 (black bars) and pri-let-7a-1 (white bars) transcripts. The values were normalized to
GAPDH levels. The fold change in the corresponding pri-miRNA abundance mediated by RNAi was plotted relative to values from
a mock-transfected control, which were set to 100. (D) Small RNA-seq analysis of MSI2 and HuR knockdown. The top graph shows
a comparison of mock-treated HeLa cells and MSI2-depleted cells (MS2 RNAi), and the middle graph shows a comparison of mock-
treated HeLa cell and HuR-depleted cells, whereas the bottom panel shows a comparison between MSI2-depleted cells and HuR-
depleted cells. mir-7 is indicated with an arrow. Library construction, sequencing, and data analysis were performed by BGI (Beijing
Genomics Institute).
Choudhury et al.
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MSI2- and HuR-depleted cells (Fig. 5E). These results pro-
vide an explanation for concomitant effects of MSI2 and
HuR on the regulation of miR-7 biogenesis. Furthermore,
the mechanistic role of HuR may be to assist MSI2 binding
to the pri-miR-7-1 CTL, which is the actual effector that
inhibits miR-7 biogenesis.
Figure 5. HuR recruits MSI2 to the pri-miR-7-1 CTL through a direct interaction. (A) Extracts prepared from HeLa cells transfected
with pCG T7-MSI2 and pCDNA3-HuR were incubated with T7 agarose. (Lane 2) The bound proteins were separated on a 10% SDS–
polyacrylamide gel and analyzed by Western blotting with anti-HuR, anti-MSI2, or anti-SRSF1 antibodies. (Lane 3) Alternatively, the
immunoprecipitate was treated with RNases A/T1 prior to loading on the gel. Lane 1was loaded with 2% of the amount of extract used
for each immunoprecipitation. (B) Extracts prepared from HeLa cells transfected with pCG T7-MSI2 and pCDNA3-HuR were incubated
with protein A beads and anti-HuR antibody. (Lane 2) The bound proteins were separated on a 10% SDS–polyacrylamide gel and
analyzed by Western blotting with anti-HuR, anti-MSI2, or anti-SRSF1 antibodies. (Lane 3) Alternatively, the immunoprecipitate was
treated with RNases A/T1 prior to loading on the gel. Lane 1 was loaded with 2% of the amount of extract used for each
immunoprecipitation. Ethidium bromide-stained 1% agarose gel of RT–PCR assay detecting pri-miR-7-1 in input; anti-HuR
immunoprecipitation and anti-HuR immunoprecipitation with RNase treatment are shown in lanes 1–3, respectively. (C) Western
blot analysis of miR-7-1 CTL RNA pull-down in mock-, HuR- or SRSF1-depleted HeLa cell extracts for HuR, MSI2, hnRNP A1, and
SRSF1. Lanes 1–3 show loading control of HeLa cell extracts from mock, HuR RNAi, and SRSF1 RNAi, respectively. Lanes 4–6 show
reactions with beads only. Lanes 7–9 represent miR-7-1 CTL RNA pull-down in HeLa cell extracts from mock, HuR RNAi, and SRSF1
RNAi, respectively. (D,E) RNA immunoprecipitation assays of formaldehyde cross-linked HeLa cells using anti-MSI2, anti-HuR, and
anti-DGCR8 antibodies, coupled with protein-A agarose beads. qRT–PCR analysis was performed on TRIzol LS-isolated RNA with
primers detecting pri-miR-7-1 (D) and pri-let-7a-1 (E) transcripts. The percentage of immunoprecipitation was plotted relative to values
derived from IgG controls, which were set to 1. Mean values and SDs of three independent experiments are shown.
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Recombinant HuR and MSI2 bind to pri-miR-7-1
and stabilize its structure
To map the precise binding sites of HuR and/or MSI2 in
pri-miR-7-1 and to determine whether this binding in-
fluences the RNA architecture and/or thermodynamic
properties that might negatively regulate its processing,
we analyzed pri-miR-7-1 secondary structure in the
presence or absence of recombinant HuR and/or MSI2
proteins by footprint analysis. The predicted structure of
the pri-miR-7-1 RNAwas validated by in vitro probing of
radiolabeled pri-miR-7-1 RNA with lead ions—Pb (II),
which cleaves single-stranded and relaxed RNA residues;
ribonuclease T1, which cleaves exposed phosphodiester
bonds after guanosines; and ribonuclease V1, which
cleaves regions of dsRNA (Fig. 6). Addition of recombi-
nant MSI2 (Fig. 6C) to the reactions did not leave notice-
able Pb (II) footprints along the pri-miR-7-1 structure
while inducing weak ribonuclease T1 and ribonuclease
V1 footprints along the pri-miR-7-1 structure. Con-
versely, recombinant HuR (Fig. 6C) masked otherwise
pronounced Pb (II) and T1 cuts in the pri-miR-7-1 CTL
region as well as other regions of the stem–loop structure
(Fig. 6). HuR binding also resulted in the appearance of
a few additional cuts, which could have originated from
unspecific cleavage or RNA structural rearrangements.
Importantly, addition of HuR and MSI2 together resulted
in a prominent increase in ribonuclease V1 cleavage of
the pri-miR-7-1 stem–loop region (Fig. 6). This implies
a global increase of the pri-miR-7-1 rigidity, which is also
confirmed by much weaker Pb (II) cuts in the correspond-
ing region. In light of Drosha cleavage activity, which
requires auxiliary helicase activity (Fukuda et al. 2007),
stabilization of the pri-miRNA structure could exert an
inhibitory effect.
A role for HuR and MSI2 in the negative regulation of
pri-miR-1 processing was confirmed using in vitro pro-
cessing assays in astrocytoma cell extracts. Addition of
MSI2, but not of HuR, inhibited the processing of pri-
miR-7-1, confirming a direct role for MSI2 in blocking
Drosha processing (Supplemental Fig. S6). This could
imply that endogenous levels of HuR are sufficient and
not limiting for the MSI2-mediated inhibition of pri-miR-
7-1 Drosha cleavage or, alternatively, that MSI2 does not
require HuR for its recruitment in vitro. Finally, using
electrophoretic gel mobility shift analysis (EMSA) of a 59
32P-labeled pri-miR-7-1 transcript, we observed that un-
likeMSI2, HuRwas able to efficiently bind to pri-miR-7-1
(Fig. 6D). Moreover, addition of MSI2 protein to the pri-
miR-7-1/HuR complex resulted in a noticeable super-
shift, indicating that MSI2 is recruited to pri-miR-7-1
through HuR. The pri-miR-7-1/HuR/MSI2 complex was
efficiently competed by increasing excess of unlabeled
miR-7-1 CTLs but not unspecific RNA without apparent
HuR-binding sites.
HuR and MSI2 regulate miR-7 biogenesis in a human
neuronal differentiation system of SH-SY5Y cells
To confirm the physiological relevance of our findings,
we used a human neuronal differentiation model of
neuroblastoma SH-SY5Y cells. When treated with all-
trans retinoic acid (RA) and subsequently with brain-
derived neurotrophic factor (BDNF), SH-SY5Y cells give
rise to nearly pure populations of human neuron-like
cells (Encinas et al. 2000). Such differentiated cells stop
dividing and express numerous neuronal markers, such as
microtubule-associated protein 2A (MAP2A). Following
this differentiation protocol, we observed progressive
morphological changes, manifesting in neurite outgrowth
and reduced size of the cell body (Supplemental Fig. 7A).
Western blot analysis of neuronal marker MAP2A con-
firmed successful neuronal differentiation of SH-SY5Y
cells (Supplemental Fig. 7B). Importantly, expression of
both MSI2 and HuR was significantly reduced only at the
last stage of differentiation, after treatment with BDNF
(Supplemental Fig. 7B). To see whether HuR andMSI2 are
inhibiting miR-7 biogenesis during SH-SY5Y differentia-
tion, we tested the levels of mature and primary miRNA
transcripts by qRT–PCR. Treatment of SH-SY5Y cells
with RA did not result in significant changes in miR-7
levels (Supplemental Fig. 7C); however, treatment with
BDNF resulted in an approximately twofold increase in
the relative abundance of miR-7 (Supplemental Fig. 7C),
displaying a negative relationship of miR-7 levels with
HuR and MSI2 expression patterns. The levels of let-7
were also elevated, most likely due to differentiation-
dependent repression of Lin28 protein. In contrast, the
levels of miR-302a did not change significantly during
differentiation (Supplemental Fig. 7C). Notably, the levels
of miR-7 and miR-302a primary transcripts were largely
unchanged throughout SH-SY5Y differentiation (Supple-
mental Fig. 7D). To ensure that HuR and MSI2 regulate
miR-7 biogenesis in SH-SY5Y cells, we used siRNA-
mediated depletion, as in HeLa cells in Figure 4. In-
dividual knockdowns of HuR and MSI2 as well as double
knockdown of HuR and MSI2 resulted in an approxi-
mately twofold increase in the relative abundance of
miR-7 (Supplemental Fig. S8). PA2G4 and SRSF1 knock-
downs did not change the levels of miR-7 (Supplemental
Fig. S8). The levels of both the miR-7 and let-7a primary
transcripts remained unchanged. Altogether, these re-
sults ascertain the physiological relevance of MSI2/
HuR-dependent inhibition of miR-7 biogenesis.
MSI2 KO mice display elevated levels of miR-7
in selected tissues without apparent change
in the pri-miR-7-1 abundance
Finally, we took advantage of a MSI2 KO model to
illustrate the physiological significance of our findings.
Western blot analysis of MSI2 in selected tissues from
a wild-type mouse revealed that MSI2 exists as multiple
isoforms in all tissues analyzed except for the brain and is
almost undetectable in the liver (Fig. 7A,B). In contrast,
HuR is detected at very low levels in the brain, the liver,
and muscle-derived samples. Analysis of miR-7 levels by
qRT–PCR confirmed its enrichment in the brain of
a wild-type mouse (Fig. 7C). In contrast, the levels of
pri-miR-7-1 did not change significantly across tissues
with the exception of the thymus, where relatively low
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Figure 6. Recombinant HuR binds directly to the pri-miR-7-1 CTL and recruits MSI2, increasing the rigidity of the stem–loop
structure. (A) Structure probing and footprint analysis of the pri-miR-7-1 in complex with HuR and/or MSI2 proteins. Cleavage patterns
were obtained for 59 32P-labeled pri-miR-7-1 transcript (100 3 103 cpm, ;40 pmol, 4 mM) incubated in the absence (lanes 1,2,8,9,15,16)
or presence of recombinant MSI2 (200 ng, 500 nM) (lanes 3,10,17), HuR (200 ng, 500 nM) (lanes 4,11,18), and both proteins (200 ng, 500
nM) (lanes 5,12,19) treated with Pb (II) lead ions (0.5 mM), ribonuclease T1 (1.5 U/mL), and ribonuclease V1 (0.025 U/mL). F (lanes
6,13,20) and T (lanes 7,14,21) denote nucleotide residues subjected to partial digestion with formamide (every nucleotide) or
ribonuclease T1 (G-specific cleavage), respectively. Electrophoresis was performed in a 6% polyacrylamide gel under denaturing
conditions. The positions of selected G residues are indicated. Nucleotides are numbered from the 59 site of Drosha cleavage. (B)
Proposed structure of free and HuR/MSI2-bound pri-miR-7-1 (additionally supported by the RNA pull-down results presented in Fig. 3;
Supplemental Fig. 3). The sites and intensities of cleavages generated by structure probes (presented below) within the pre-miR-7-1
region are shown. The asterisk indicates selected intrinsic or protein-induced in-line autocatalytic RNA cleavages. (C) Silver-stained
4%–12% Novex Tri-Bis SDS-PAGE of recombinant MSI2 (100 ng) (lane 2) and recombinant HuR (100 ng) (lane 3) shows the quality of
the proteins (OriGene Technologies). (Lane 1) BenchMark prestained protein ladder indicates approximate molecular weights. The
proteins migrate similarly to corresponding endogenous proteins detected by relevant antibodies. (D) EMSA of pri-miR-7-1 with the
MSI2 and HuR proteins. Electrophoresis was performed in a 5% polyacrylamide gel under native conditions. Prior to electrophoresis, 59
32P-labeled pri-miR-7-1 transcript (50 3 103 cpm, ;20 pmol, 2 mM) was incubated without proteins (lane 1) or in the presence of
recombinant MSI2 (200 ng, 500 nM) (lane 2), HuR (200 ng, 500 nM) (lane 3), or both proteins (200 ng, 500 nM) (lane 4). miR-7-1 and
unspecific indicate unlabeled RNA competitors; (+) 5 pmol; (++) 50 pmol; (+++) 500 pmol.
Figure 7. Brain-enriched miR-7 is up-regulated in a MSI2 KO mouse. (A) Western blot analysis of protein extracts from wild-type mouse
tissues using anti-MSI2, anti-HuR, and anti-tubulin. (Lane 1) Brain. (Lane 2) Colon. (Lane 3) Heart. (Lane 4) Kidney. (Lane 5) Liver. (Lane 6)
Lung. (Lane 7) Spleen. (Lane 8) Stomach. (Lane 9) Thymus. (Lane 10) Muscle. (B) Western blot analysis of protein extracts from selected
MSI2 KO mouse tissues. Lanes 1, 3, 5, and 7 indicate extracts from a wild-type mouse, whereas lanes 2, 4, 6, and 8 show proteins derived
from a MSI2 KO mouse. (C) Real-time qRT–PCR on miRNAs from 1 mg of total RNA from select wild-type mouse tissues reveals
a substantial enrichment of miR-7 (black bars) in brain tissue and a different pattern of let-7a (white bars) in select tissues. The values were
normalized to 5S levels. The fold change of miR abundance was plotted relative to the values from brain total RNA, which were set to
100. (D) Real-time qRT–PCR on pri-miRNAs from samples as shown inA show a lack of significant correlation with the abundance of the
corresponding mature miRNAs (correlation coefficient = 0.16, P-value = 0.33). Values were normalized to GAPDH levels. The fold change
of pri-miRNA abundance was plotted relative to the values from brain total RNA, which were set to 100. (E) Real-time qRT–PCR on miR-7
from total RNA samples derived from wild-type (black bars) and MSI2 KO (white bars) mice show a large increase in the levels of miR-7
in MSI2 KO tissues. Values were normalized to 5S levels. The fold change of miR-7 abundance was plotted relative to values derived from
the wild-type mouse, which were set to 100. (F) Real-time qRT–PCR on let-7a from total RNA samples derived from wild-type (black bars)
and MSI2 KO (white bars) mice. Data are presented as in E. (G,H) Real-time qRT–PCR on pri-miR-7-1 and pri-let-7a-1 from samples as
shown in E show very little difference between the wild-type and MSI2 KO mice. Values were normalized to GAPDH levels. The fold
change of pri-miR abundance was plotted relative to the values from the wild-type mouse, which were set to 100.
levels of mature miR-7 are found (Fig. 7D). This strongly
supports the existence of post-transcriptional control of
miR-7 abundance in mammalian cells. Similar results
were obtained when human RNA from selected tissues
was analyzed (Supplemental Fig. S9). Crucially, miR-7
levels were elevated in the MSI2 KO mouse from twofold
to 20-fold depending on the tissue type, with the highest
increases observed in the brain and stomach (Fig. 7E). Let-
7a displayed a modest increase in only a few tissues when
compared with miR-7 (Fig. 7F). Importantly, the relative
abundance of pri-miR-7-1 and pri-let-7a-1 transcripts
remained similar in the MSI2 KO and the wild-type mice,
with exception of stomach tissue, where we observed a
twofold increase in pri-miR-7-1 and pri-let-7a-1 abun-
dance (Fig. 7G,H).
In summary, we revealed a novel molecular mecha-
nism that controls brain-enriched miRNA biogenesis by
neural-depleted factors. Our results strongly suggest a role
for the MSI2 and HuR proteins in binding to pri-miR-7-1
and the negative regulation of tissue-specific miR-7 pro-
duction at the post-transcriptional level in mammalian
tissues.
Discussion
In eukaryotic cells, miRNA levels are tightly controlled,
and their dysregulation is a hallmark of many human
diseases, including cancer (Davis and Hata 2010). Increas-
ing evidence suggests that the biogenesis of miRNAs is
regulated at different steps by a variety of protein factors
that bind to the CTL elements of pre-miRNAs and pri-
miRNAs (Winter et al. 2009; Krol et al. 2010). For ex-
ample, the Lin28 proteins (Lin28a and Lin28b) mediate
the CTL-dependent inhibition of let-7 biogenesis in un-
differentiated cells and at early stages of embryonic de-
velopment (Rybak et al. 2008; Viswanathan et al. 2008). It
has been shown that the binding of Lin28a to the CTL of
pre-let-7 induces 39-terminal uridylation through the
recruitment of TUT4 polymerase (Heo et al. 2008, 2009;
Jones et al. 2009; Nam et al. 2011), thereby preventing
efficient processing of pre-let-7 by Dicer, which in turn
leads to active degradation of the transcript (Heo et al.
2009). Additionally, it has been demonstrated that Lin28b
functions in the nucleus by sequestering primary let-7
transcripts and inhibiting their processing by Micropro-
cessor (Piskounova et al. 2011). We showed recently that
the RNA-binding protein hnRNP A1 acts as a negative
regulator of let-7a processing in somatic cells that lack
Lin28 (Michlewski and Caceres 2010a). hnRNP A1 binds
to the CTL of pri-let-7a-1 and inhibits its processing by
Drosha by interfering with the binding of the KSRP
protein, which is known to promote let-7a biogenesis
(Trabucchi et al. 2009).
Here, we reveal the first example of defined factors that
control tissue-enriched miRNA maturation. We demon-
strate a lack of positive correlation between the levels of
mature miR-7 and the pri-miR-7-1 transcript in human
cells and tissues, which is indicative of the existence of a
post-transcriptional mechanism controlling miR-7 abun-
dance. Previously, it was suggested that the SR protein
SRSF1 positively regulates the processing of miR-7 by
binding to the pri-miR-7-1 stem and competing with
canonical miRNA processing factors (Wu et al. 2010). In
our experimental conditions, the efficient knockdown of
SRSF1 in HeLa cells did not result in a noticeable change
in miR-7 levels (Fig. 4). Recently, it was shown that HuR
depletion in HeLa cells results in a significant induction
of miR-7 without an apparent change in the levels of the
pri-miR-7-1 transcript (Lebedeva et al. 2011). While con-
firming this observation, we also found other miRNAs
whose abundance is changed upon HuR depletion. Im-
portantly, cross-linking immunoprecipitation (CLIP) anal-
ysis of HuR-binding sites failed to detect the CTL region
of pri-miR-7-1 or its immediate flanking sequence. Here,
we demonstrate that HuR inhibits miR-7 biogenesis by
binding to the CTL of pri-miR-7-1. The failure to detect
CLIP tags over the CTL region of the pri-miR-7-1 may be
due to the rapid turnover of miR-7 containing the hnRNP
K intron. Notably, the HuR protein is expressed ubiqui-
tously throughout human tissues, unlike its neuronal
homologs, HuB, HuC, and HuD (Ma et al. 1996). Further-
more, in our experiments, we detected similar levels of
HuR in astrocytoma and HeLa cells expressing high and
low levels of miR-7, respectively. Additionally, the CTL
of pri-miR-7-1 pulled down HuR with the same efficiency
from astrocytoma and HeLa cell extracts. All of these
observations suggest that HuR alone is not sufficient for
the repression of miRNA processing and that, in the case of
miR-7, there is another factor that limits its biogenesis in
most human cells and allows its expression in neural cells.
Using methodology that allows for the comprehensive
characterization of proteins that bind to a defined RNA
molecule in a given experimental condition, we identified
the MSI2 protein, which is preferentially expressed and
bound to the pri-miR-7-1 CTL in HeLa cell extracts.
Recently, a similar methodology using tobramycin RNA
affinity chromatography coupled with quantitative mass
spectrometry was used to identify proteins that bind
dengue virus untranslated regions (UTRs) (Ward et al.
2011). It was previously shown that during neurogenesis,
the expression of MSI2 is lost in post-mitotic neurons
(Sakakibara et al. 2001). Moreover, Northern blot analysis
of the MSI2 transcript in human tissues showed low
levels in the brain compared with other tissues (Barbouti
et al. 2003). In agreement, we showed that the levels of
both MSI2 and HuR proteins were significantly reduced
during neuronal differentiation of human neuroblastoma
SH-SY5Y cells and displayed an opposing expression
pattern to the miR-7 abundance. It was previously noted
that miR-7 levels are increased during differentiation of
SH-SY5Y cells (Le et al. 2009). Crucially, we show that
a MSI2 KO mouse, which displays aberrant regulation of
hematopoietic stem cells (de Andres-Aguayo et al. 2011),
has elevated levels of miR-7 when compared with the
wild-type mouse. This up-regulation was detected with-
out apparent changes in the levels of miR-7 primary
transcript. We also validated our findings using global
miRNA profiling with small RNA-seq. Independent knock-
down of MSI2 and HuR resulted in a significant increase of
the miR-7 levels. However, the observed change in miR-7
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levels upon HuR knockdown was lower than the one
reported earlier (Lebedeva et al. 2011), being more in line
with our qRT–PCR results. This discrepancy could be due
to a different HeLa strain used in our study, RNAi effi-
ciency, sample processing, and data analysis. Surprisingly,
we found other miRNAs (for example, pri-miR-505, pri-
miR-92a-1, and pri-miR-224) that are coregulated by MSI2
and HuR. It remains to be established whether these
miRNAs undergo similar tissue-specific regulation of their
biogenesis. In summary, all of these results strongly indicate
that theMSI2 andHuR proteins have a physiological role in
inhibition of miR-7 biogenesis in mammalian cells.
miR-7 is also present in pancreatic cells. Since pancre-
atic and neuronal differentiation lineages are closely
related (Zhao et al. 2007), it will be interesting to deter-
mine whether a similar mechanism of miRNA regula-
tion operates in pancreatic tissues. Recently, it has been
demonstrated that MSI1, a close homolog of MSI2, works
in conjunction with Lin28 to regulate let-7 biogenesis at
the level of Drosha cleavage (Kawahara et al. 2011). Here,
we demonstrate that HuR recruits MSI2 to the pri-miR-
7-1 CTL. Therefore, MSI2 is likely the regulatory inhib-
itor of miR-7 biogenesis, and the role of HuR may be
limited to strengthening the interaction between the pri-
miR-7-1 CTL and MSI2. Finally, we show that the HuR/
MSI2 complex increases the rigidity of the pri-miR-7-1
stem–loop structure. Due to the fact that the Micropro-
cessor cleavage is dependent on DEAD-box RNA helicase
activity (Fukuda et al. 2007), such stabilization provides a
mechanistic clue into the inhibitory effect of MSI2/HuR
on the processing of pri-miR-7.
Aberrant miRNA expression has been linked to a vari-
ety of human pathological states, including cancers
(Ventura and Jacks 2009). Furthermore, analysis of gene
expression in primary tumors indicates widespread de-
fects in the post-transcriptional regulation of miRNA
processing (Thomson et al. 2006; Lee et al. 2008). Cru-
cially, miR-7 expression has been shown to be down-
regulated in high-grade glioblastomas without an appar-
ent change in the levels of pri-miR-7 transcripts (Kefas
et al. 2008). Dysregulation of miR-7 leads to the activa-
tion of epidermal growth factor receptor (EGFR), a protein
responsible for initiating uncontrolled cell division
(Nicholson et al. 2001). Interestingly, the 39 UTR of
mouse EGFR does not have miR-7-binding sites while
sharing binding sites with the human EGFR 39 UTR for
miR-133 and miR-27 (TargetScan, release 6.2, June 2012).
Thus, the physiological activity of MSI2/HuR-mediated
inhibition in mice will most likely be exerted through yet
unknown targets. Both HuR and MSI2 are overexpressed
in numerous human malignancies, including brain can-
cers (Nabors et al. 2001; Hinman and Lou 2008; Moore
2010). Furthermore, MSI2 plays important roles in nor-
mal and malignant hematopoiesis (de Andres-Aguayo
et al. 2012). Therefore, the identified inhibitors of miR-7
biogenesis likely have a direct role inmodulating the levels
of miR-7 and its targets under physiological and path-
ological conditions. Indeed, according to the Oncomine
database (Rhodes et al. 2007), there is a clear link between
the expression of EGFR, HuR, and MSI2 in glioblastoma
samples (Supplemental Fig. S10). Importantly, our find-
ings suggest that disrupting the interaction between HuR
and MSI2 could have a positive effect on miR-7 and other
HuR/MSI2-regulated miRNAs, implicating this interac-
tion as a potential target for anti-cancer therapy.
Materials and methods
Cell culture, RNAi, and differentiation conditions
HeLa, human brain astrocytoma 1321N1, 293T, and neuroblas-
toma SH-SY5Y cells were grown in DMEM (Life Technologies)
supplemented with 10% (v/v) fetal calf serum (FCS). RNAi exper-
iments were performed using Lipofectamine 2000 (Life Technolo-
gies) following the manufacturer’s instructions. Transfected cells
were incubated with the corresponding 50 nM Silencer Select
predesigned and validated siRNAs for 72 h. Plasmids expressing
recombinant proteins (500 ng per well of a six-well plate) or pri-
miRNAs (50 ng per well of a six-well plate) were transfected for
24 h. Differentiation of SH-SY5Y cells was performed according to
a protocol described before (Le et al. 2009). In short, cells were
seeded on collagen-coated plates (Life Technologies). On the fol-
lowing day, all-trans RA (Sigma) was added at the final concentra-
tion of 10 mM. After 5 d, the cells were washed three times with
DMEM and incubated with 50 ng/mL BDNF (Sigma) and incubated
in serum-free medium for 4 d.
Protein expression plasmids
The plasmid expressing HuR (pCDNA3-HuR) was a gift from Joan
Steitz (Myer et al. 1997). The pri-miR-7-1 sequence was amplified
by PCR with oligonucleotides miR-7-1_for_XbaI (TTTTCTAGA
AAAACTGCTGCCAAAACCAC) and miR-7-1_rev_BamHI (AA
AGGATCCGCTGCATTTTACAGCACCAA) and cloned into the
XbaI and BamHI sites of the pCG-T7 mammalian expression
vector (Caceres et al. 1997). MSI2 cDNAwas amplified from total
HeLa RNAusing the SuperScript III PlatinumOne-Step qRT–PCR
kit (Life Technologies) with oligonucleotides MSI2_for (GGCTC
AGATATGGAGGCAAA) andMSI2_rev (AAAAGGAGAATGGG
AAGAGAGG). Next, the MSI2 ORF was PCR-amplified using
MSI2_for_XbaI (TTTTCTAGAGAGGCAAATGGGAGCCAAG
GC) and MSI2_rev_BamHI (AAAGGATCCTCAATGGTATCC
ATTTGTAAAG) and cloned into the XbaI and BamHI sites of
the pCG-T7 mammalian expression vector to produce the pCG
T7-MSI2 plasmid.
Western blot analysis
HeLa, astrocytoma, 293T, or SH-SY5Y cells were scraped and
sonicated in buffer D as described above. Total protein extracts
(100 mg), proteins obtained from RNase-assisted RNA pull-down
(Michlewski and Caceres 2010b), or coimmunoprecipitations
were separated by SDS-PAGE and electroblotted onto nitrocellu-
lose membranes (Whatman) in 25 mM Tris-base, 40 mM glycine,
and 20% (v/v) methanol in a Genie Blotter unit (Idea Scientific
Company) at 12 V for 1 h. Nonspecific binding sites were blocked
by incubating the membrane with 1:10 Western blocking solution
(Roche) in TBST (20 mM Tris at pH 7.5, 137 mMNaCl, 0.1% [v/v]
Tween 20). Proteins were detected using the following primary
antibodies diluted in 1:20 Western blocking solution in TBST:
mousemonoclonal anti-hnRNPA1 (clone 4B10; 1:1000; SantaCruz
Biotechnology), rabbit polyclonal anti-HuR (1:1000; Millipore),
rabbit polyclonal anti-MSI2 (clone EP1305Y; 1:1000; Millipore),
rabbit polyclonal anti-MSI1 (1:000; GeneTex), rabbit polyclonal
anti-PA2G4 (1:1000; Sigma), rabbit polyclonal anti-TIA-1 (1:1000;
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Santa Cruz Biotechnology), rabbit polyclonal anti-hnRNP K
(1:1000; Cell Signaling Technology), mouse monoclonal anti-
SRSF1 (clone 96; 1:500) (Hanamura et al. 1998), rabbit poly-
clonal anti-MAP2A (1:1000; Cell Signaling Technology), rabbit
polyclonal anti-Drosha (1:1000; Cell Signaling Technology),
rabbit polyclonal anti-DGCR8 (N-terminal, 1:1000; Sigma),
and mouse-monoclonal anti-b-tubulin (1:10,000; Sigma). After
washing in TBST, the blots were incubated with the appropriate
secondary antibodies conjugated to horseradish peroxidase
(Pierce) and detected with SuperSignal West Pico detection
reagent (Thermo Scientific). The membranes were stripped
using ReBlot Plus Strong Antibody Stripping solution (Chem-
icon), equilibrated in water, blocked in 1:10 Western blocking
solution in TBST, and reprobed as described above. Proteins
were also visualized by a Silver staining kit (Pierce Thermo
Scientific), according to the manufacturer’s instructions.
MSI2 KO mouse
The MSI2 deficient mouse cell line (MSI2 Gt/Gt) was generated
by insertional mutagenesis in a large-scale gene trap screen
(German Gene Trap Consortium [GGTC]) as described in de
Andres-Aguayo et al. (2011). The MSI2Gt/Gt mouse is a func-
tional knockout; thus, for the purpose of this study, we call it the
MSI2 KO mouse.
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